

# Yury Shvarts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4887905/publications.pdf>

Version: 2024-02-01

42  
papers

20,129  
citations

304368

22  
h-index

377514

34  
g-index

45  
all docs

45  
docs citations

45  
times ranked

22096  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of sudden cardiac death in strength training. Russian Journal of Cardiology, 2022, 26, 4394.	0.4	1
2	Measures of chronic heart failure as the markers of cognitive dysfunction in patients with coronary heart disease complicated by circulatory failure. Cor Et Vasa, 2021, 63, 20-24.	0.1	0
3	Cardiovascular risk factors and blood pressure response to various types of exercise in veteran athletes. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2575.	0.4	1
4	Symptomatic hypotensive episodes in patients with hypertension. Relationship with blood pressure self-monitoring parameters. Russian Journal of Cardiology, 2021, 26, 4440.	0.4	0
5	Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial. Clinical Therapeutics, 2021, 43, 1720-1734.	1.1	2
6	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology, 2021, 78, 421-433.	1.2	58
7	Characteristics of hippocampus, cognitive functions, lipid profile, and severity of chronic heart failure in patients with coronary heart disease. Cor Et Vasa, 2020, 62, 29-32.	0.1	1
8	Hypertension in people in middle and late adulthood during sports and physical training. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 5-10.	0.4	1
9	Hypertension in people in middle and late adulthood during sports and physical training. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 5-10.	0.4	0
10	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, 2019, 7, 618-628.	5.5	207
11	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, 2019, 394, 1169-1180.	6.3	155
12	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine, 2019, 380, 1509-1524.	13.9	833
13	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, 2019, 393, 1937-1947.	6.3	408
14	Vascular control parameters and gene polymorphism associated with cardiovascular risk in young and relatively healthy individuals. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 45-50.	0.4	2
15	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	13.9	2,211
16	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 1118-1127.	13.9	205
17	PROGNOSTIC SIGNIFICANCE OF THE VNTR POLYMORPHISM INTRON 4 OF THE GENE OF NITRIC OXIDE ENDOTHELIAL SYNTHASE IN CHRONIC HEART FAILURE PATIENTS. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 37-42.	0.4	0
18	ARTERIAL HYPERTENSION AT SPORT ACTIVITIES IN MIDDLE AGE AND ELDERLY SPORTSMEN. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 20-24.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	13.9	4,179
20	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
21	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	13.9	6,227
22	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	40
23	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	13.9	379
24	Cause of Death and Predictors of Allâ€Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
25	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
26	Polymorphism of genes associated with increased cardiovascular risk and cognitive function in patients with chronic heart failure and in healthy persons: the pilot study. <i>Russian Open Medical Journal</i> , 2015, 4, e0102.	0.1	1
27	GENE POLYMORPHISM IN ASSOCIATION WITH ATHEROSCLEROSIS DEVELOPMENT AND COGNITION DISORDERS IN PATIENTS WITH ISCHEMIC CHRONIC HEART FAILURE. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2015, 14, 30.	0.4	1
28	Interaction Between Digoxin and Dronedarone in the PALLAS Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 1019-1025.	2.1	66
29	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 252.	3.8	270
30	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006.	3.8	375
31	Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1870.	3.8	422
32	RED BLOOD VALUES CHANGES IN CARDIOVASCULAR PATIENTS â€” EPIDEMIOLOGY, PROGNOSIS AND TREATMENT APPROACHES. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2014, 13, 62-67.	0.4	2
33	ACUTE MYOCARDIAL INFARCTION SPECIFICS IN PATIENTS WITH CHRONIC TONSILLITIS. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2014, 13, 22-26.	0.4	0
34	INTERRELATION OF ATHEROSCLEROSIS RISK FACTORS AND CENTRAL NERVOUS SYSTEM CONDITION IN PATIENTS WITH CHRONIC HEART FAILURE OF ISCHEMIC ORIGIN. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2014, 13, 36-40.	0.4	0
35	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	13.9	2,261
36	PROGRESSING CHRONIC KIDNEY DISEASE AND THE 12-MONTH DYNAMICS OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2013, 12, 16-21.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Combination of coronary heart disease, chronic heart failure, and anaemic syndrome: clinical features and prognostic impact of anaemia treatment. Russian Journal of Cardiology, 2013, , 105-111.	0.4	1
38	COGNITIVE DYSFUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION: ASSESSING THE ROLE OF VASCULAR FACTORS. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 58-62.	0.4	0
39	Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2268-2276.	13.9	547
40	Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity and Metabolism, 2009, 11, 611-622.	2.2	272
41	Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. Circulation, 2005, 111, 3411-3419.	1.6	251
42	Polymorphism of ACE, AGT, AGTR1 genes as genetic predictors of hypertension. Russian Journal of Cardiology, 0, 26, 4143.	0.4	5